



Imugene lead product HER-Vaxx patent application receives US Notice of Allowance

- *Imugene's biggest intellectual property milestone*
- *Patent will give method of composition and method of use protection to 2030*

Melbourne, 29 July 2014: Australian biopharmaceutical company Imugene Limited (ASX:IMU) has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for Patent Application 13/389419 (2030 expiry) which protects its HER-Vaxx cancer immunotherapy, currently in development for gastric cancer.

The patent titled "Multiepitope Vaccine for HER2/Neu-associated Cancers" protects the method of composition and method of use of Imugene's HER-Vaxx for the generation of a therapeutic antibody response against HER-2/neu.

HER-Vaxx is a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu, the same biomarker targeted by the \$US6.9 billion per annum drug Herceptin®. HER-Vaxx has successfully completed a Phase 1 study in breast cancer and the next stage of development will be a Phase 2 study in gastric cancer.

Dr Nick Ede, Executive Director Imugene said, "Attaining the key US patent is the biggest milestone for almost every biotechnology company. This adds extra value to HER-Vaxx as this will protect it in the world's largest pharmaceutical market until 2030."

Gastric or stomach cancer is the second most common cause of cancer-related death in the world and the fourth most commonly diagnosed cancer, with over 1,000,000 new cases diagnosed each year.

Contact :

Paul A Hopper
Executive Chairman
+1 858 334 5820 (US)
+61 406 671 515 (Australia)
receptogen[at]earthlink.net

Dr Nick Ede
Executive Director
+61 400 642 254
nede[at]imugene.com

Media contact:

Rudi Michelson
Monsoon Communications
+61 3 9620 3333
rudim[at]monsoon.com.au

About Imugene: Imugene (ASX; IMU) is an immuno-oncology biopharmaceutical company developing HER2 +ve gastric and breast cancer immunotherapies. The Company's lead product is HER-Vaxx, a proprietary HER2 +ve cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours including gastric, breast, ovarian, lung and pancreatic cancers. HER-Vaxx has successfully completed a Phase I study in breast cancer and the next stage of development will be a Phase II study in gastric cancer. Imugene's corporate headquarters are located in Melbourne, Australia with the scientific team in Vienna, Austria. For more information on Imugene, please visit www.imugene.com